GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
14 août 2024 08h05 HE
|
GRI Bio, Inc.
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and...